Black Diamond (BDTX) director awarded 40,000 stock options at $1.71

Rhea-AI Filing Summary

Black Diamond Therapeutics director Ali Behbahani received a grant of stock options covering 40,000 shares of common stock at an exercise price of $1.71 per share. The options expire on June 25, 2036 and were granted as a compensation award, not an open-market purchase.

According to the terms, all 40,000 options will vest and become exercisable on the earlier of June 26, 2027 or the company’s next annual meeting of stockholders, provided Behbahani continues to serve as a director through that date. After this grant, his directly held option position reported in this filing totals 40,000 options.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Behbahani Ali

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 40,000 options Exercise price: $1.71 per share Underlying shares: 40,000 shares +4 more

7 metrics

Options granted 40,000 options Stock Option (Right to Buy) grant to director

Exercise price $1.71 per share Strike price for the 40,000 options

Underlying shares 40,000 shares Common stock underlying the option grant

Vesting date Earlier of June 26, 2027 or next annual meeting Subject to continued board service

Expiration date June 25, 2036 Option term end for this grant

Options held after grant 40,000 options Total directly held options reported in this filing

Transaction code A Grant, award, or other acquisition of derivative security

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vesting, +2 more

6 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.7100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-25T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The shares subject to this option shall vest and become exercisable in full"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:41 PM Accepted by SEC EDGAR 06/29/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Behbahani Ali

(Last) (First) (Middle)

2855 SAND HILL RD

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.71	06/26/2026		A		40,000		(1)	06/25/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Zachary Bambach, attorney-in-fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Black Diamond Therapeutics (BDTX) director Ali Behbahani report on this Form 4?

Ali Behbahani reported receiving a grant of stock options for 40,000 shares of Black Diamond Therapeutics common stock. The award is a compensation grant, not an open-market stock purchase or sale, and is structured as a right to buy shares at a fixed exercise price.

How many Black Diamond Therapeutics (BDTX) options were granted and at what exercise price?

Behbahani was granted stock options covering 40,000 shares of Black Diamond Therapeutics common stock at an exercise price of $1.71 per share. This price is the cost he must pay per share if he chooses to exercise the options once they have vested.

When do Ali Behbahani’s Black Diamond Therapeutics (BDTX) options vest?

All 40,000 options will vest and become exercisable on the earlier of June 26, 2027 or Black Diamond Therapeutics’ next annual meeting of stockholders. Vesting is conditional on Behbahani continuing to serve as a director through the applicable vesting date specified in the award terms.

When do the granted Black Diamond Therapeutics (BDTX) options expire?

The granted stock options expire on June 25, 2036 if not exercised. After that expiration date, Behbahani would no longer be able to purchase Black Diamond Therapeutics shares under this particular option award, even if they have fully vested beforehand.

Is this Black Diamond Therapeutics (BDTX) Form 4 a stock purchase or sale?

This Form 4 reflects a stock option grant, not a direct share purchase or sale in the open market. Behbahani received the right to buy up to 40,000 shares at $1.71 per share in the future, subject to vesting and the 2036 expiration date.